Skip to main
  1. Stocks
  2. Vaxcyte
  3. Forecast
PCVX

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte is fundamentally attractive because OPUS-1 delivered a near-clean sweep for VAX-31, with all 20 shared serotypes versus PCV20 meeting the stringent non-inferiority bar and 17 of 19 versus PCV21, while also showing a safety profile similar to both comparators. That result materially de-risks the adult program, supports broad label potential from launch, and strengthens the company’s competitive position in an $8B+ pneumococcal market where coverage breadth matters for payers and physicians. The outlook is further supported by a deep pipeline and upcoming catalysts, including pediatric data expected by the end of 1H27, VAX-A1 phase 1 data in 2H27, and a BLA submission targeted for the first half of 2028.

Bears say

Vaxcyte is facing a pressured fundamental setup because challenging market conditions and the near-term catalyst path imply limited visibility until potentially eight months to value-inflecting pediatric phase 2 data, while the shares are also exposed to typical financing pressure. Its vaccine pipeline remains highly uncertain, as VAX-31 and other candidates must prove safety, efficacy, and meaningful differentiation against approved, well-established pneumococcal vaccines and competitors with greater resources. Financially, profitability is not expected for several years, additional capital may be required, and development, regulatory, manufacturing, commercial, and patent risks could all impair long-term value creation.

Vaxcyte (PCVX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Vaxcyte (PCVX) Analyst Forecast & Price Prediction

Get the latest Vaxcyte (PCVX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Vaxcyte (PCVX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Vaxcyte (PCVX) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $117.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $117.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Vaxcyte (PCVX) Analyst Forecast & Price Prediction

Get the latest Vaxcyte (PCVX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Vaxcyte (PCVX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PCVX stock data and trends